Company news
Armata Pharmaceuticals, Inc. (AMEX:ARMP) news
Armata Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 23, 2026: Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding…
Press releases & updates
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
September 23, 2026
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
September 21, 2026
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
September 14, 2026
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
September 3, 2026
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
August 12, 2026
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
July 20, 2026
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
July 13, 2026
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
June 23, 2026
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
May 13, 2026
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
May 7, 2026
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
May 4, 2026
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
April 27, 2026
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
March 25, 2026
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
March 19, 2026
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
February 23, 2026
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia
January 14, 2026
/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./
January 13, 2026
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
November 18, 2025
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
November 12, 2025
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
November 10, 2025
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
October 22, 2025
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
October 14, 2025
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
September 8, 2025
Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
August 12, 2025
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
May 19, 2025
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
May 14, 2025
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
May 1, 2025
Armata Pharmaceuticals : 2025 Annual Meeting Proxy
April 29, 2025
Armata Pharmaceuticals : Annual Report Package for the 2025 Annual Meeting
April 23, 2025
Armata Pharmaceuticals : Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP PA02 in Non Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection Form 8 K
December 19, 2024
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
November 20, 2024
Armata Pharmaceuticals : Announces Third Quarter 2024 Results and Form 8 K
November 13, 2024
Armata Pharmaceuticals : Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia Form 8 K
November 12, 2024
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 6, 2024